Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Hyun Woo LeeSeung Soo Sheen

Abstract

Alterations in apoptosis and DNA damage repair related proteins are associated with resistance to chemotherapy, which is the most important cause of treatment failure in advanced non-small cell lung cancer (NSCLC). Pretreatment tumor biopsy specimens from 50 patients with NSCLC including stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based third-generation doublet chemotherapy, in which gemcitabine and cisplatin was the most commonly administered regimen (17 patients). High expression of p53, Bcl-2, Bax, and ERCC1 was observed in 24 (48%), 8 (16%), 32 (63%), and 28 (55%) patients, respectively. In univariate analysis, high expression of ERCC1 demonstrated a trend of association with poor overall survival (OS) (median, 8 months vs. 11 months; P=0.055). High expression of p53, Bcl-2, Bax was not correlated with patient outcome. High expression of ERCC1 was an independent prognostic factor for poor OS (P=0.002) along with poor performance status (P=0.028) and lack of disease control (P=0.001) in multivariate analysis. High expression of ERCC1 may be a useful prognostic factor for poo...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Sep 26, 2003·Seminars in Surgical Oncology·Merrill J Solan, Maria Werner-Wasik
Jan 23, 2004·The New England Journal of Medicine·Alexander Spira, David S Ettinger
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rafael RosellUNKNOWN Spanish Lung Cancer Group
Feb 26, 2004·Seminars in Oncology·Rafael RosellRosario García-Campelo
Feb 26, 2004·Seminars in Oncology·Sakkaraiappan Ramalingam, Chandra P Belani
May 4, 2005·Biochemical and Biophysical Research Communications·Kristina ViktorssonRolf Lewensohn
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sunil SinghalSteven M Albelda
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eddie Reed
Sep 20, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·F M WachtersH J M Groen
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Sep 19, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CeppiG V Scagliotti
Nov 27, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kyung-Hun LeeJoo Hyun Kim
Jan 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Primo N LaraUNKNOWN Southwest Oncology Group
Apr 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hai-Rim ShinUNKNOWN 139 KCCR-affiliated Hospitals

❮ Previous
Next ❯

Citations

Mar 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A C VilmarJ B Sørensen
Oct 6, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A C VilmarJ B Sorensen
Mar 24, 2011·The Cancer Journal·Jenny AndrewsLeora Horn
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Alec VaeziLaura J Niedernhofer
Nov 17, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·E Giroux LeprieurM Wislez
Jun 15, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sufeng ChenHaiquan Chen
Apr 21, 2010·Revue des maladies respiratoires·D PlanchardJ-C Soria
Nov 17, 2009·Critical Reviews in Oncology/hematology·Giannis MountziosChristos A Papadimitriou
Apr 15, 2014·Biochimica Et Biophysica Acta·Elaina N MaginnEuan A Stronach
Jan 7, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Anne-Claire ToffartElisabeth Brambilla
Sep 3, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Helen VassalouDimitris Mavroudis
Jul 28, 2016·Journal of Cancer Research and Therapeutics·Guo-Yin LiTao Liu
Jul 13, 2013·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Mihir R PatelD Neil Hayes
May 19, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Guoping Li, Dan Cheng
Jun 30, 2011·Virchows Archiv : an International Journal of Pathology·Hans BösmüllerFalko Fend
Apr 22, 2010·Cancer Research·Ken André Olaussen, Jean-Charles Soria
Sep 9, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennis Shin-Shian HsuMuh-Hwa Yang
Jun 22, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam Christian VilmarJens Benn Sørensen
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A C VilmarJ B Sorensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis